

Finn K Hansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2282119/publications.pdf>

Version: 2024-02-01

67
papers

1,488
citations

279798

23
h-index

330143

37
g-index

73
all docs

73
docs citations

73
times ranked

2060
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiproliferation and Anticystation Effect of Class II Histone Deacetylase Inhibitors on <i>Acanthamoeba castellanii</i> . <i>ACS Infectious Diseases</i> , 2022, 8, 271-279.	3.8	9
2	Comparison of Cellular Target Engagement Methods for the Tubulin Deacetylases Sirt2 and HDAC6: NanoBRET, CETSA, Tubulin Acetylation, and PROTACs. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 138-140.	4.9	10
3	Balancing Histone Deacetylase (HDAC) Inhibition and Drug-Likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors. <i>ChemMedChem</i> , 2022, , .	3.2	10
4	Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin-HDAC Inhibitor Hybrids as Multitarget Drugs. <i>Pharmaceuticals</i> , 2022, 15, 333.	3.8	4
5	Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain. <i>Pharmaceuticals</i> , 2022, 15, 324.	3.8	0
6	Development of a First-in-Class Small-Molecule Inhibitor of the C-Terminal Hsp90 Dimerization. <i>ACS Central Science</i> , 2022, 8, 636-655.	11.3	12
7	A Novel Zinc Binding Group for HDAC6 Inhibition. <i>FASEB Journal</i> , 2022, 36, .	0.5	2
8	Investigation of the <i>in vitro</i> and <i>in vivo</i> efficacy of peptoid-based HDAC inhibitors with dual-stage antiplasmodial activity. <i>European Journal of Medicinal Chemistry</i> , 2021, 211, 113065.	5.5	8
9	Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile. <i>Chemical Science</i> , 2021, 12, 11873-11881.	7.4	8
10	Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. <i>Cancers</i> , 2021, 13, 634.	3.7	96
11	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 211, 113095.	5.5	8
12	Hybrid Peptides Based on β -Aminoxy Acids as Antimicrobial and Anticancer Foldamers. <i>ChemPlusChem</i> , 2021, 86, 827-835.	2.8	2
13	Oxa Analogues of Nexturastatins...A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity. <i>ChemMedChem</i> , 2021, 16, 1799-1804.	3.2	4
14	Call for Papers: "Epigenetics 2.0" A Joint Virtual Special Issue on Epigenetics. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1262-1263.	4.9	0
15	Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells. <i>Anticancer Research</i> , 2021, 41, 2901-2912.	1.1	4
16	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14620-14646.	6.4	22
17	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by <i>Journal of Medicinal Chemistry</i> , <i>ACS Medicinal Chemistry Letters</i> , and <i>ACS Pharmacology & Translational Science</i> . <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13935-13936.	6.4	3
18	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by <i>Journal of Medicinal Chemistry</i> , <i>ACS Medicinal Chemistry Letters</i> , and <i>ACS Pharmacology & Translational Science</i> . <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1508-1509.	2.8	2

#	ARTICLE	IF	CITATIONS
19	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, and ACS Pharmacology & Translational Science. ACS Pharmacology and Translational Science, 2021, 4, 1712-1713.	4.9	0
20	The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells. Anticancer Research, 2021, 41, 5987-5996.	1.1	0
21	Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors. International Journal of Molecular Sciences, 2020, 21, 8300.	4.1	10
22	Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs). Angewandte Chemie - International Edition, 2020, 59, 22494-22499.	13.8	42
23	In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi). International Journal of Molecular Sciences, 2020, 21, 4747.	4.1	3
24	Hydroxamic Acids Immobilized on Resins (HAIRs): Synthese von Dual-Targeting HDAC-Inhibitoren und HDAC-PROTACs. Angewandte Chemie, 2020, 132, 22681-22687.	2.0	2
25	Editorial: Chemical Innovative Approaches in Cancer Molecular Medicine and Translational Clinical Research. Frontiers in Chemistry, 2020, 8, 820.	3.6	0
26	Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups. Journal of Medicinal Chemistry, 2020, 63, 10339-10351.	6.4	27
27	Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics. Bioorganic and Medicinal Chemistry, 2019, 27, 115039.	3.0	18
28	Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE. ACS Medicinal Chemistry Letters, 2019, 10, 1336-1340.	2.8	30
29	Structure-Activity and Structure-Toxicity Relationships of Peptoid-Based Histone Deacetylase Inhibitors with Dual-Stage Antiplasmodial Activity. ChemMedChem, 2019, 14, 912-926.	3.2	24
30	Design, synthesis and biological evaluation of β -peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity. MedChemComm, 2019, 10, 1109-1115.	3.4	11
31	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties. Journal of Medicinal Chemistry, 2019, 62, 11260-11279.	6.4	27
32	Histone deacetylase inhibitors with high in vitro activities against Plasmodium falciparum isolates collected from Gabonese children and adults. Scientific Reports, 2019, 9, 17336.	3.3	11
33	Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor. Journal of Medicinal Chemistry, 2018, 61, 10299-10309.	6.4	62
34	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites. European Journal of Medicinal Chemistry, 2018, 158, 801-813.	5.5	29
35	Multicomponent Synthesis and Binding Mode of Imidazo[1,2- <i>a</i>]pyridine-Capped Selective HDAC6 Inhibitors. Organic Letters, 2018, 20, 3255-3258.	4.6	43
36	Effects of novel HDAC inhibitors on urothelial carcinoma cells. Clinical Epigenetics, 2018, 10, 100.	4.1	51

#	ARTICLE	IF	CITATIONS
37	Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. <i>Blood</i> , 2018, 132, 307-320.	1.4	66
38	Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8054-8060.	6.4	76
39	Î±-Aminoxy Peptoids: A Unique Peptoid Backbone with a Preference for cis-Amide Bonds. <i>Chemistry - A European Journal</i> , 2017, 23, 3699-3707.	3.3	9
40	Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5493-5506.	6.4	32
41	Design and Synthesis of Novel Anti-Plasmodial Histone Deacetylase Inhibitors Containing an Alkoxyamide Connecting Unit. <i>Archiv Der Pharmazie</i> , 2017, 350, 1600347.	4.1	9
42	Design and Synthesis of Terephthalic Acid-Based Histone Deacetylase Inhibitors with Dual-Stage Anti-Plasmodium Activity. <i>ChemMedChem</i> , 2017, 12, 1627-1636.	3.2	14
43	Isophthalic Acid-Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from <i>Schistosoma mansoni</i> . <i>Archiv Der Pharmazie</i> , 2017, 350, 1700096.	4.1	16
44	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5334-5348.	6.4	37
45	EDTA aggregates induce SYPRO orange-based fluorescence in thermal shift assay. <i>PLoS ONE</i> , 2017, 12, e0177024.	2.5	27
46	Î±-Aminoxy Oligopeptides: Synthesis, Secondary Structure, and Cytotoxicity of a New Class of Anticancer Foldamers. <i>Chemistry - A European Journal</i> , 2016, 22, 17600-17611.	3.3	16
47	HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. <i>Human Molecular Genetics</i> , 2016, 25, 3887-3907.	2.9	77
48	HDAC5 controls the functions of Foxp3 ⁺ T _H regulatory and CD8 ⁺ T cells. <i>International Journal of Cancer</i> , 2016, 138, 2477-2486.	5.1	67
49	Class I HDACs specifically regulate E-cadherin expression in human renal epithelial cells. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2289-2298.	3.6	32
50	Synthesis, Antimalarial Properties, and SAR Studies of Alkoxyurea-Based HDAC Inhibitors. <i>ChemMedChem</i> , 2014, 9, 665-670.	3.2	26
51	Lysine Acetylation in Sexual Stage Malaria Parasites Is a Target for Antimalarial Small Molecules. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3666-3678.	3.2	62
52	Design, Synthesis, and Conformational Analysis of Trispyrimidonamides as Î±-Helix Mimetics. <i>Journal of Organic Chemistry</i> , 2014, 79, 1582-1593.	3.2	5
53	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. <i>European Journal of Medicinal Chemistry</i> , 2014, 82, 204-213.	5.5	68
54	Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 427-436.	6.4	152

#	ARTICLE	IF	CITATIONS
55	Capture of benzotriazole-based Mannich electrophiles by CH-acidic compounds. RSC Advances, 2013, 3, 4152.	3.6	3
56	Expedient Microwave-Assisted Synthesis of Novel 6-Substituted 5-Alkoxy(benzyloxy)-3,6-dihydro-2H-1,3,4-oxadiazin-2-ones. Synlett, 2012, 23, 637-639.	1.8	2
57	Efficient Microwave-Assisted Synthesis of 1,2,4-Triazole-Based Peptidomimetics Using Benzotriazole Methodology. Heterocycles, 2012, 84, 515.	0.7	4
58	Efficient synthesis and 5-LOX/COX-inhibitory activity of some 3-hydroxybenzo[b]thiophene-2-carboxylic acid derivatives. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5031-5034.	2.2	17
59	Long-Range Intramolecular S → N Acyl Migration: A Study of the Formation of Native Peptide Analogues via 13-, 15-, and 16-Membered Cyclic Transition States. Journal of Organic Chemistry, 2012, 77, 2637-2648.	3.2	28
60	Efficient synthesis of flupirtine analogues derived from pyrimidine. Journal of Heterocyclic Chemistry, 2012, 49, 321-328.	2.6	2
61	A New Benzotriazole-Mediated Stereoflexible Gateway to Heterodiketopiperazines. Chemistry - A European Journal, 2012, 18, 2632-2638.	3.3	18
62	Efficient microwave-assisted synthesis of aminoxy acid conjugates. RSC Advances, 2011, 1, 602.	3.6	4
63	Microwave-assisted chemical ligation of S-acyl peptides containing non-terminal cysteine residues. Organic and Biomolecular Chemistry, 2011, 9, 7162.	2.8	18
64	Facile Synthesis and <i>In Vitro</i> Antimalarial Activity of Novel α -Hydroxy Hydrazonates. Archiv Der Pharmazie, 2011, 344, 755-764.	4.1	1
65	Synthesis of Novel N,3-Substituted 3H-[1,2,3]Triazolo[4,5-d]pyrimidin-5-amines. Synthesis, 2010, 2010, 689-693.	2.3	1
66	Convenient Synthesis of 5-Substituted 2-Amino[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(6H)-ones from N-Triazolide Imidates and 1,2,4-Triazole-3,5-diamine. Synthesis, 2010, 2010, 1645-1648.	2.3	4
67	Expedient Microwave-Assisted Synthesis of 5-Benzoylamino-2-(aralkylsulfanyl)pyrimidin-4(3H)-ones. Synthesis, 2010, 2010, 2583-2587.	2.3	0